NCT03748641 2026-03-16
MAGNITUDE
Janssen Research & Development, LLC
Phase 3 Active not recruiting
Clinical Trials
10 trialsNCT05968599 2026-02-25
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
Pfizer
Completed
NCT03016741 2026-02-24
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
Northwestern University
Phase 4 Active not recruiting
NCT03431350 2025-12-23
QUEST
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT05393791 2024-11-26
ANZadapt
Leiden University Medical Center
Phase 2 Recruiting
NCT05520138 2024-09-27
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
Pfizer
Completed
NCT04844749 2024-02-05
VERACITY
Veru Inc.
Phase 3 Terminated
NCT03173859 2020-11-18
AERA
University of Athens
Phase 2 Withdrawn
NCT03325127 2018-10-31
Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study
Bayer
Withdrawn
NCT02254785 2017-12-06
Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer
British Columbia Cancer Agency
Phase 2 Unknown